Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults

Drugs of Today

Volumn 49, Issue 6, 2013, Pages 353-361

  Gras, Jordi ^a  

^a not available   (Spain)

Author keywords

Anti infective therapy; Antimycobacterial agent; Bedaquiline; MDR TB; TMC 207; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CYTOCHROME P450 3A4; ETHAMBUTOL; ISONIAZID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SUTEZOLID;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84880025472     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.6.1970865     Document Type: Article

References (54)

1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO. Geneva, 2010. http://www.who.int/tb/publications/2010/9789241547833/en/ index.html. Accessed April 2, 2013.
2. Tuberculosis. Fact sheet No 104. Reviewed February 2013. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed April 4, 2013.
3. Lienhardt, C., Raviglione, M., Spigelman, M. et al. New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospects for the future. J Infect Dis 2012, 205(Suppl. 2): S241-9.
4. McIlleron, H., Meintjes, G., Burman, W.J., Maartens, G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007, 196(Suppl. 1): S63-75. (Pubitemid 47206086)
5. Shah, N.S., Wright, A., Bai, G.-H. et al. Worldwide emergence of extensively drug resistant tuberculosis. Emerg Infect Dis 2007, 13(3): 380-7. (Pubitemid 46348124)
6. Orenstein, E. W., Basu, S., Shah, N.S. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9(3): 153-61.
7. Mitnick, C., Bayona, J., Palacios, E. et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348(2): 119-28. (Pubitemid 36056718)
8. Andries, K., Verhasselt, P., Guillemont, J. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307(5707): 223-7. (Pubitemid 40116230)
9. Guillemont, J., Koen, A., Peter, V., Nacer, L., Vincent, J. The diarylquinoline (DARQ) series. A new class of anti-tuberculosis agents. Drugs Fut 2006, 31(Suppl. A): Abst L89.
10. FDA approves first drug to treat multi-drug resistant tuberculosis [news release]. U.S. Food and Drug Administration, December 31, 2012. Accessed March 18, 2013.
11. Treatment Action Group. An activist's guide to bedaquiline (Sirturo). http://www.treatmentactiongroup.org/tb/publications/2013/activist-guide- bedaquiline. Accessed March 18, 2013.
12. Arjona, A., Castañer, R. TMC-207. Drugs Fut 2008, 33(12): 1018-24.
13. Andries, K., Guillemont, J., Bush, K., Williams, P., Cambau, E., Truffot-Pernot, C., Jarlier, V. Diarylquinolines (DARQ), a novel class of anti-tuberculosis agents. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-1113.
14. Huitric, E., Verhasselt, P., Andries, K., Hoffner, S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007, 51(11): 4202-4. (Pubitemid 350057830)
15. Protopopova, M., Hanrahan, C., Nikonenko, B. et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005, 56(5): 968-74. (Pubitemid 41631930)
16. Reddy, V.M., Einck, L., Andries, K., Nacy, C.A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010, 54(7): 2840-6.
17. Wallis, R.S., Jakubiec, W., Mitton-Fry, M. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 2012, 7(1): e30479.
18. Jarlier, V., Lounis, N., Veziris, N., Truffot-Pernot, C., Ji, B., Guillemont, J., Andries, K. Potent activity of a novel diarylquinoline (DARQ) in murine tuberculosis. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-1114.
19. Veziris, N., Ibrahim, M., Lounis, N., Truffot-Pernot, C., Andries, K., Jarlier, V. R207910 is very active when administered once-a-week in murine tuberculosis. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst B-736.
20. Veziris, N., Ibrahim, M., Lounis, N., Chauffour, A., Truffot-Pernot, C., Andries, K., Jarlier, V. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009, 179(1): 75-9.
21. Veziris, N., Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V. R207910 containing regimens display high sterilizing activity in the murine model of tuberculosis. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst B-1225.
22. Andries, K., Gevers, T., Lounis, N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 2010, 54(11): 4540-4.
23. Tasneen, R., Li, S.Y., Peloquin, C.A. et al. Sterilizing activity of novel TMC207- and PA-824-Containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011, 55(12): 5485-92.
24. Tasneen, R., Li, S., Andries, K., Mdluli, K., Nuermberger, E. Novel TMC207-containing regimens have sterilizing activity in murine tuberculosis. 51st Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2011, Abst B-1205.
25. Shang, S., Shanley, C.A., Caraway, M.L. et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 2011, 55(1): 124-31.
26. Gelber, R., Andries, K., Paredes, R.M., Andaya, C.E., Burgos, J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009, 53(9): 3989-91.
27. Koul, A., Dendouga, N., Vergauwen, K. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007, 3(6): 323-4. (Pubitemid 46789271)
28. Huitric, E., Verhasselt, P., Koul, A., Andries, K., Hoffner, S., Andersson, D.I. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010, 54(3): 1022-8.
29. Segala, E., Sougakoff, W., Nevejans-Chauffour, A., Jarlier, V., Petrella, S. New mutations in the mycobacterial ATP synthase: New insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012, 56(5): 2326-34.
30. Haagsma, A.C., Abdillahi-Ibrahim, R., Wagner, M.J. et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009, 53(3): 1290-2.
31. Biukovic, G., Basak, S., Manimekalai, M.S. et al. Variations of subunit epsilon of the mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207. Antimicrob Agents Chemother 2013, 57(1): 168-76.
32. Rouan, M.C., Anciaux, K., Vermeir, M. et al. Preclinical pharmacokinetics, metabolism and distribution of TMC207, a novel anti-tuberculosis agent. 9th Int ISSX Meet (Sept 4-8, Istanbul) 2010, Abst P111.
33. NDA 204-384. Sirturo™ (bedaquiline 100 mg tablets) for the treatment of adults (≥ 18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). Applicant: Janssen Research and Development, L.L.C http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329258. pdf. Accessed March 26, 2013.
34. Rouan, M.C., Lounis, N., Gevers, T., Dillen, L., Gilissen, R., Raoof, A., Andries, K. Pharmacokinetics and pharmacodynamics of TMC207 and its n-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012, 56(3): 1444-51.
35. van Heeswijk, R., Vandevoorde, A., Meyvisch, P., De Marez, T., Dannemann, B., Hoetelmans, R. The pharmacokinetics of TMC207, an investigational antimycobacterial agent, in subjects with moderate hepatic impairment. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1260.
36. Fox, W., Ellard, G.A., Mitchison, D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3(10, Suppl. 2): S231-79. (Pubitemid 29481843)
37. Van Heeswijk, R., Lachaert, R., Leopold, L., De Beule, K., McNeeley, D., Hoetelmans, R. The pharmacokinetic (PK) interaction between isoniazid/ pyrazinamide and TMC207, an investigational anti-mycobacterial agent. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-780.
38. Everitt, D., Winter, H., Egizi, E. Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentine. 19th Int AIDS Conf (July 22-27, Washington, D.C.) 2012, Abst MOAB0304.
39. van Heeswijk, R., Diacon, A., Pym, A., Meyvisch, P., De Marez, T., Dannemann, B., Hoetelmans, R. The pharmacokinetics (PK) of second line antituberculosis agents with and without TMC207, an investigational anti mycobacterial agent, in patients with MDR-TB. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1258.
40. van Heeswijk, R., Vandevoorde, A., Meyvisch, P., De Marez, T., McNeeley, D., Hoetelmans, R. The effect of nevirapine on the pharmacokinetics of TMC207, an investigational antimycobacterial agent, in HIV-1-infected subjects. 6th IAS Conf HIV Pathog Treat Prev (July 17-20, Rome) 2011, Abst MOPE172.
41. Vrouenraets, S.M., Wit, F.W., van Tongeren, J., Lange, J.M. Efavirenz: a review. Expert Opin Pharmacother 2007, 8(6): 851-71. (Pubitemid 46736458)
42. Dooley, K.E., Park, J.G., Swindells, S. et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (Bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J Acquir Immune Defic Syndr 2012, 59(5): 455-62.
43. Svensson, E., Dooley, K.E., Aweeka, F., Park, J., Karlsson, M.O. Population pharmacokinetics (PK) of TMC207 and its M2 metabolite with efavirenz (EFV) demonstrate reduced exposure. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1256.
44. van Heeswijk, R., Vandevoorde, A., Meyvisch, P., De Marez, T., De Beule, K., Mc Neeley, D., Hoetelmans, R. The effect of lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent. 18th Int AIDS Conf (July 18-23, Vienna) 2010, Abst WEPE0097.
45. Diacon, A.H., Donald, P.R., Pym, A. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56(6): 3271-6.
46. Diacon, A.H., Pym, A., Grobusch, M. et al. Interim analysis of a double-blind, placebo-controlled study with TMC207 in patients with multi-drug resistant (MDR) tuberculosis. 48th Annu Intersci Conf Antimicrob Agents Chemother (ICAAC) Infect Dis Soc Am (IDSA) Annu Meet (Oct 25-28, Washington, D.C.) 2008, Abst B-881b.
47. Diacon, A.H., Pym, A., Grobusch, M. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360(23): 2397-405.
48. Diacon, A.H., Pym, A., Grobusch, M.P. et al. Final results from stage 1 of a double-blind, placebo-controlled trial with TMC207 in patients with multi-drug resistant (MDR) tuberculosis (TB). 50th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 12-15, Boston) 2010, Abst L1-521a.
49. Diacon, A.H., Dawson, R., von Groote-Bidlingmaier, F. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 2012, 380(9846): 986-93.
50. Diacon, A., Dawson, R., Van Niekerk, C., Erondu, N., Ginsberg, A. Pyrazinamide increases the early bactericidal activity of TMC207 and PA-824 in patients with newly diagnosed, smear-positive pulmonary tuberculosis. 51st Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2011, Abst P-931a.
51. Everitt, D., Murray, S., Diacon, A. et al. A phase 2 trial of novel anti-tuberculosis regimens with increased efficacy and low potential to interact adversely with antiretroviral therapy. 19th Int AIDS Conf (July 22-27, Washington, D.C.) 2012, Abst MOAB0305.
52. Good, C.E., Healan, A.M.B., Blumer, J.L. et al. Whole blood mycobactericidal activity (WBA) of bedaquiline (BDQ, TMC207) alone and in combination with rifampin (RIF) or rifabutin (RBT) after oral dosing of healthy volunteers. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1257.
53. Dannemann, B.R., Bakare, N., De Marez, T. et al. Corrected QT interval (QTcF) prolongation in a phase 2 open-label trial of TMC207 plus background regimen (BR) as treatment for MDR-TB: Effect of coadministration with clofazimine (CFZ). 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1259.
54. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results? term=bedaquiline&Search=Search, http://clinicaltrials.gov/ct2/results?term= TMC207&Search=Search. Accessed March 18, 2013.